- Previous Close
0.9900 - Open
1.0200 - Bid 0.7210 x 200
- Ask 1.2700 x 200
- Day's Range
0.9699 - 1.0506 - 52 Week Range
0.5310 - 2.3500 - Volume
6,362 - Avg. Volume
30,463 - Market Cap (intraday)
23.265M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.69
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
renovorx.comRecent News: RNXT
View More
Performance Overview: RNXT
Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNXT
View MoreValuation Measures
Market Cap
23.75M
Enterprise Value
12.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-70.08%
Return on Equity (ttm)
-155.12%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.11M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
11.74M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.62M
Research Analysis: RNXT
View MoreCompany Insights: RNXT
RNXT does not have Company Insights